UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2010

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California	**001-14758**	**33-0476164**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

3260 Whipple Road Union City, California	**94587**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(510) 400-0700**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On June 10, 2010, Questcor Pharmaceuticals, Inc. (the "Company") will be making presentations to certain members of the investment community and, in connection therewith, will advance a presentation (the "Presentation") providing certain information about the Company. This Presentation will be made available on the Company's website at www.Questcor.com as soon thereafter as practicable. The Presentation is furnished under this Item 7.01 pursuant to Regulation FD and is included as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under such section, nor shall it be deemed incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	***Description***
99.1	Presentation made by Questcor Pharmaceuticals, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 10, 2010

QUESTCOR PHARMACEUTICALS, INC.

By: /s/ Gary M. Sawka
Gary M. Sawka
Senior Vice President, Finance and
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation made by Questcor Pharmaceuticals, Inc.


QUESTCOR
June 2010
NASDAQ: QCOR
QUESTCOR

Cautionary Statement

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "if," "should," "forecasts," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: Questcor's ability to continue to successfully implement its Acthar-centric business strategy, including its expansion in the MS marketplace and other therapeutic areas; FDA approval of and the market introduction of competitive products and our inability to market Acthar in IS prior to approval of IS as a labeled indication; Questcor's ability to operate within an industry that is highly regulated at both the Federal and state level; Regulatory changes or other policy actions by governmental authorities and other third parties as recently adopted U.S. healthcare reform legislation is implemented, or new healthcare-related legislation is enacted; Questcor's ability to accurately forecast the demand for its products; Questcor's ability to receive high reimbursement levels from third party payers; Questcor's ability to estimate the quantity of Acthar used by government entities and Medicaid-eligible patients; that the actual amount of rebates and chargebacks related to the use of Acthar by government entities, including the Department of Defense Tricare network, and Medicaid-eligible patients may differ materially from Questcor's estimates; Questcor's expenses and other capital needs for upcoming periods; the inventories carried by Questcor's distributors, specialty pharmacies and hospitals; Volatility in Questcor's monthly and quarterly Acthar shipments and end-user demand; the complex nature of Questcor's manufacturing process and the potential for supply disruptions or other business disruptions; Questcor's ability to attract and retain key management personnel; Research and development risks, including risks associated with Questcor's sNDA for IS and its preliminary work in the area of nephrotic syndrome; uncertainties regarding Questcor's intellectual property; the uncertainty of receiving required regulatory approvals in a timely way, or at all; the impact to Questcor's business caused by economic conditions; Questcor's limited pipeline for new products and its ability to identify product acquisition candidates and consummate transactions on terms acceptable to the Company; and Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2009, Form 10-Q for the quarter ended March 31, 2010, and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.

Questcor Overview

- *Flagship product: H.P. Acthar® Gel (Acthar)*
- *Key markets: Multiple Sclerosis, Infantile Spasms, Nephrotic Syndrome*
- *Strategy: grow share in these three markets*
- *Financials: profitable, debt-free, $91M in cash, cash flow positive*

H.P. Acthar® Gel

- Highly purified preparation of adrenocorticotropic hormone (ACTH)
- Key approved indications:
  - Multiple sclerosis (MS) exacerbations
  - Nephrotic syndrome
- Significant off-label usage

H.P. Acthar Gel
Significant barriers to entry

- Natural-source biologic involving 39 amino acid ACTH plus multiple peptide fragments
- Complex, multi-step manufacturing process involving extensive proprietary know-how
- Very difficult to reproduce by competitor or generic company

Questcor Growth Engine

- **Multiple Sclerosis**
  - From near zero to over $45M run rate in 24 months
  - $500M+ market with little competition
- **Infantile Spasms**
  - FDA approval could help increase Acthar's already leading market share
- **Nephrotic Syndrome**
  - On-label market >$1B
  - Pilot sales effort started

Multiple Sclerosis

- Neurodegenerative disorder affecting 400,000 people in the US
- An estimated 200-250,000 exacerbations among MS patients in the US annually
- Market research indicates 10-20,000+ patients per year are candidates for Acthar treatment
- $500 million to over $1 billion potential market
  - Approximately 3-6X infantile spasms (IS) market

H.P. Acthar® Gel and MS

- Acthar indicated for treatment of exacerbations associated with MS
- Small but growing number of Acthar prescribers
  - Currently <400 out of 2,500 MS specialists
  - Q1 sales—over $45M annualized run rate
  - Significant upside potential

Targeted Selling Effort in MS

- **Positioning: for select MS flare patients who …**



MS Sales Results—Rxs Filled



QUESTCOR

MS Prescriber Growth

(Based on Shipped Rxs)



MS Rxs Shipped/Paid vs Calls



MS Sales Growth History

- Q1-2010 results
  - Q1-10 new Rxs ↑ 197% vs Q109
  - MS sales now exceed IS sales
- Repeat patients are now >20% of total MS patients prescribed Acthar
- Expanded sales force
  - Expanded sales force 4 times in last 2 years
  - Sales increased each time

Infantile Spasms

- Devastating, refractory form of childhood epilepsy
  - Very poor developmental outcome if inadequately treated
- Not responsive to standard anti-epileptic drugs
- Ultra-orphan disorder
  - 1,500 to 2,000 patients annually
- Typically occurs in children less than 2 years old
- Characterized by
  - "spasms" -- a specific type of seizure
  - "hypsarrhythmia" -- abnormal EEG pattern

H.P. Acthar® Gel and IS

- Used by many child neurologists
  - Despite lack of indication for IS
- Key scientific publications
  - Joint CNS, AAN, AES guidelines (Mackay, et al. 2004)
  - Pivotal clinical trial data (Baram, et al. 1996)
- Few therapeutic alternatives for IS patients
- Successful advisory panel 5/6/10

Trends in IS Sales

- Significant quarterly variability
- Q1-2010 sales within historic range
  - Acthar currently used to treat 30-50% of IS patients
  - No significant impact from Q409 Sabril launch
- Major IS symposium at Q409 CNS mtg
  - Reinforced key 1st line role for Acthar in IS treatment

Gain IS indication

- **Timeline**
  - sNDA accepted 12/23/09
  - Positive Advisory Panel Meeting 5/6/10
  - PDUFA pending
- **Prepare for Q4 sales launch**
  - Gain 7 year orphan exclusivity
  - Ability to actively educate providers on proper Acthar dosing and patient monitoring
  - Potential to increase IS revenue 10-30%

Nephrotic Syndrome: Significant unmet need

- Characterized by excessive spilling of protein from the kidney into the urine (proteinuria)
- Nephrotic-range proteinuria caused by a number of underlying kidney diseases and disorders
  - Membranous nephropathy
  - Lupus nephritis
  - Focal segmental glomerular sclerosis (FSGS)
  - Diabetic nephropathy
- Can result in serious health outcomes
  - End-stage renal disease, dialysis, transplant
- Few treatment options
- Represents a significant unmet medical need

Nephrotic Syndrome: Sizable market for H.P. Acthar® Gel

- H.P. Acthar® Gel is indicated …
  - To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
- Leading nephrologists very supportive of possible use of Acthar
- Pilot sales effort starting Q210
  - Expand selling effort if pilot is successful
- Possible market opportunity for Acthar estimated to be > $1B

Case Study: Acthar in Nephrotic Syndrome

- 58 year old white male with ESRD due to idiopathic membranous nephropathy
  - Underwent kidney transplant approximately 5 years ago, and has done very well to date
- Patient history includes post-transplant Diabetes Mellitus, HBV & HCV infection, and coronary artery disease
- Current meds include Tacrolimus (Prograf), Mycophenolate Mofetil (Cellcept), Vytorin

Case Study: Acthar in Nephrotic Syndrome

- Noted “new bubbles” in his urine*
  - 24-hr urine protein 4851 mg (previously <200 mg)
- Biopsy performed one month later
  - Mild thickening detected in the glomerular basement membrane of the transplanted kidney
  - *Diagnosis >> nephrotic syndrome due to membranous nephropathy*

* Sudden and significant increase in bubbles in urine can be the first sign of worsening proteinuria

Case Study: Acthar in Nephrotic Syndrome

- **Labs before Acthar**
  - *24-hr urine 4851 mg/day protein*

>>> Acthar treatment initiated

- **Labs -- 4 weeks after starting Acthar (40U twice weekly)**
  - *24-hr urine 3757 mg/day protein*
- **Labs -- 8 weeks after starting Acthar (80U twice weekly)**
  - *24-hr urine 1332 mg/day*
- **Labs -- 24 weeks after starting Acthar (80U twice weekly)**
  - *24-hr urine 500 mg/day*

- ***>>> Patient met criteria for complete remission after 6 months of Acthar – now off Acthar, still in remission***

Immediate Acthar Growth Opportunities

- MS--Build on sales momentum
- IS--Grow market share after obtaining FDA approval
- NS--Pursue Nephrotic Syndrome as new therapeutic use; expand pilot sales effort

Financials

Profitable, debt free, and cash flow positive

Quarterly Results

	Q1-2010	Q1-2009
Net Sales ($M)	**$ 26.2**	**$23.3**
Gross Margin	92%	94%
Income Before Taxes ($M)	$ 12.1	12.2
EPS	**$ 0.12**	**$0.11**

Q1 2010 Analysis

- MS sales up 197% YOY
- IS sales within historic range
- Modest set of nephrotic syndrome Rxs
- Solid profitability and cash generation

Balance Sheet ~ $1.47/share in cash

	06/04/10
Cash/ST Investments	$91M*
Accounts Receivable	$14M

*After return of $67 million of cash to shareholders through share repurchases.

QUESTCOR IS CASH FLOW POSITIVE

Share repurchases: 14 Million shares in 2008-2009

- 2.2 Million Preferred share buyback
- 12.4 Common share buyback
- $67 million returned to shareholders in stock buybacks
- 62 million shares currently outstanding
- 5.1 million shares remain on buyback authorization

REPURCHASES SIGNIFICANTLY IMPROVE EPS

Go Forward Plan- Sell More Acthar

- Expand Sales Force to pursue MS, IS and NS markets
  - Approximately double the sales team by Q4
- Focus on Acthar
  - Develop other markets for Acthar
  - Acthar is its own pipeline with many possible other therapeutic uses
  - Suspend business development efforts

QUESTCOR

Investment Highlights

- Questcor is streamlined, focused & profitable
- H.P. Acthar® Gel has sustainable competitive advantages
- Substantial growth in MS sales
- Significant upside with NS (on-label)
- Market sizes have good growth potential
- Cash flow positive/no debt
- Significant sales expansion program

QUESTCOR

June 2010

NASDAQ: QCOR